By Michael Susin
NuCana's American depositary receipts nearly doubled on Monday after the company reported positive data for its metastatic melanoma treatment.
In premarket trading ADRs were up $2.44 to $4.98. However, ADRs are down more than 80% on a 52-week basis.
The U.K. company said final data from the study of its asset NUC-7738 in combination with pembrolizumab in patients with metastatic melanoma showed a prolonged progression free survival, a positive disease control rate and a favorable safety profile.
The company said that nine of the 12 patients achieved a disease control, including a patient who achieved a 55% reduction in tumor volume. Seven of them had a progression free survival time of greater than five months, which is highly atypical in this patient population, the company added.
"Outcomes in this patient population are very poor, with median progression free survival of two to three months with the current standard of care, so we are very encouraged that the majority of patients who received this combination achieved a progression free survival of more than five months," Chief Executive Hugh Griffith said.
Write to Michael Susin at michael.susin@wsj.com
(END) Dow Jones Newswires
September 16, 2024 06:18 ET (10:18 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。